InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article
August 23, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Partners with Calvert Labs, Gad Consulting Services to Conduct Preclinical Bridging Studies in Preparation for Phase 2b Clinical Trials
August 19, 2021
Tryp Therapeutics recently announced new agreements with Calvert Labs and Gad Consulting Services, the second in a series of upcoming bridging studies aimed at facilitating the advancement of TRP-8803 into Phase 2b clinical trials Calvert Labs will design and execute the exploratory studies, while Gad Consulting Services will advise on certain aspects of the studies […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Standing Distinct in Psychedelic-Derived Treatments Space
August 17, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is focused on driving significant innovation with its drug development pipeline. Tryp is leveraging its Psilocybin-for-Neuropsychiatric Disorders (“PFN”) program in the development of treatments for chronic pain indications including fibromyalgia, phantom limb pain and complex regional pain syndrome. In addition, the company is preparing to initiate a phase 2a […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Insights on the Psychedelics Space on The Dealmaker Podcast
August 13, 2021
Mr. Greg McKee, CEO of Tryp Therapeutics, appeared on The Dealmaker Podcast to share insights on the company and the psychedelics industry During the interview, he discussed the potential of psychedelics in the treatment of PTSD and other mental disorders Greg also shared the challenges that the industry is facing currently, mostly to do with […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnerships to Explore, Develop Proprietary Psilocybin Formulations
August 10, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has signed agreements with both Calvert Labs and Gad Consulting Services to design, execute and collaborate on exploratory studies related to Tryp’s Psilocybin-for-Neuropsychiatric Disorders, or PFN(TM) (“PFN”), program. An Altasciences company, Calvert Labs […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present Flagship PFN Program at 2021 Canaccord Genuity Virtual Growth Conference
August 5, 2021
The company will present an overview of business operations and its pipeline, including the Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program for chronic pain and eating disorders The initial indication of lead drug candidate TRP-8802 is for fibromyalgia, but Tryp believes that psilocybin can be used for much more in the realm of unmet medical needs PFN’s development […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured on The Dealmaker Show, to Present at Canaccord Genuity Annual Growth Conference
August 3, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was featured on The Dealmaker Show, a fast-paced and high-energy forum hosted by bestselling author Oren Klaff. Tryp’s CEO and Chairman Greg McKee joined the latest episode to discuss the company’s […]
InvestorBrandNetwork Announces The Dealmaker Show Interview with Tryp Therapeutics Inc. CEO Greg McKee
August 3, 2021
LOS ANGELES, Aug. 03, 2021 (GLOBE NEWSWIRE) — via InvestorWire –InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces that Greg McKee, Chairman & CEO of Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs, recently appeared on The Dealmaker Show, a fast-paced and […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Exploring Psilocybin Treatments in Underserved Indications
July 30, 2021
NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Psychedelics — Not Just for Mental Health Anymore.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/i3ouS While it is common knowledge that the use of psychedelic […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Third Quarter Numbers, Notes Q3 Investor Day
July 29, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, has reported its interim financial results; the results cover the three- and nine-month period ended May 31, 2021. Highlights of the report include Tryp’s collaboration with the Chronic Pain & Fatigue Research […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Developing Evidence-Based Innovation Where Drugs Are Lacking
July 28, 2021
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Psychedelics — Not Just for Mental Health Anymore,” […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Board Appointments
July 26, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced the appointment of Robin Carhart-Harris, Ph.D. as chairman of Tryp’s Scientific Advisory Board (“SAB”) and Daniel Clauw, M.D. as a new member of the SAB. Dr. Carhart-Harris initially joined […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Preview Milestones for Novel Psychedelic Therapies in Investor Day Event
July 22, 2021
Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program Tryp’s management team […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), University of Michigan to Collaborate in Phase 2a Clinical Trial for Fibromyalgia
July 21, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced its plans to conduct a phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Enters Agreement with University of Michigan for Testing of Latest Psychedelic Drug Candidate
July 16, 2021
San Diego-based Tryp Therapeutics is developing new drug candidates with the aim of treating medical conditions that currently have limited effective therapy Tryp has solidified an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to test synthetic psychedelic drug candidate TRP-8803 to advance its use […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Upcoming Q3 Investor Day
July 15, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be hosting a third-quarter virtual Investor Day. The company has scheduled this event for July 29, 2021; it will begin at 9 a.m. PDT. Included on the event agenda will […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leveraging Similar Strategy as Leading Cannabis-Derived Compound Pharmaceutical Company
July 8, 2021
Jazz Pharmaceuticals’ acquisition of GW Pharma for $7.2 billion in February 2021 shows the massive potential of the drug development industry from naturally-derived compounds Tryp Therapeutics is following in the footsteps of GW with its innovative drug pipeline and the development of psilocybin-based compounds for the treatment of diseases with high unmet medical needs It […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Strategic Collaboration with the University of Michigan
July 7, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced an agreement with the University of Michigan to perform research related to Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN(TM)”) program. According to the update, the collaboration is part of a series of […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Share its Drug Development Pipeline and the Company’s Progress in the Psych Investor Summit
July 2, 2021
Tryp Therapeutics will be participating in the second global Psych Investor Summit: Research and Development The virtual presentation is scheduled for July 7 from 11:50 a.m. to 12:50 p.m. EDT It will focus on the psychedelics industry, showcasing the latest research and development within the sector Mr. Greg McKee, Chairman and CEO of Tryp Therapeutics, […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Advance Psychedelic Medicine Program
July 1, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is partnering with pharmaceutical research companies that will provide support services for the development of its synthetic TRP-8802 psilocybin product. This is on top of a collaboration with pediatric eating disorders expert Jennifer Miller, M.D. of the University of Florida, who is directing the investigation/clinical trials of the product. […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Differentiated by Clinical Trials, World-Class Management
July 1, 2021
NEW YORK, July 01, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “GW Pharma Sells for Bilions; Psychedelic Company Following Similar Path.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/0N5t5 Many companies are angling to capitalize on the […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Charting Its Own Course in Psychedelic Space
June 30, 2021
NEW YORK, June 30, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “GW Pharma Sells for Bilions; Psychedelic Company Following […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs
June 25, 2021
In 2021, Tryp Therapeutics plans on expanding its academic collaborations It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Take Virtual Stage at Psych Investor Summit
June 24, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs, today announced that it is presenting at the Psych Investor Summit: Research & Development. The conference is slated to take place virtually on July 7. Tryp’s chairman and CEO Greg McKee will present information on the […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Featured Guest in Latest Stock2Me Podcast
June 17, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced that chairman and CEO Greg McKee was interviewed on the most recent episode of the Stock2Me Podcast. The podcast features a fascinating array of companies and individuals that are actively revolutionizing business practices within […]
InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast featuring Tryp Therapeutics Inc. Chairman and CEO Greg McKee
June 17, 2021
LOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) — (via InvestorWire) InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Stock2Me Podcast features a fascinating […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Presentation to Provide Overview of Psychedelic Drug Candidate Program at Ladenburg Thalmann Healthcare Conference
June 16, 2021
Tryp Therapeutics is a development-stage pharmaceutical company dedicated to finding novel bioscience solutions for conditions with unmet needs The company’s executive team will present an overview of its Psilocybin-For-Neuropsychiatric Disorders (“PFN”) program, in response to conditions such as fibromyalgia, at next month’s Ladenburg Thalmann Healthcare Conference Tryp’s synthetic psychedelic drug candidate will be further developed […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Collaborating to Create Safer, More Effective Protocol in ‘Fast-Moving Arena of Psychedelic Therapies’
June 15, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is collaborating with psychedelic therapy educational platform Fluence to provide design and training for the psychotherapeutic portion of its Phase 2a clinical trials for treating eating disorders and fibromyalgia. “Fluence is led by researchers and psychotherapists with direct experience in conducting psychedelic clinical trials and is the foremost provider […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference
June 10, 2021
Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021 As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program Tryp will present alongside other pharmaceutical companies leading research in […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) Announces Participation at Ladenburg Thalmann Healthcare Conference
June 8, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, will be presenting at the upcoming Ladenburg Thalmann Healthcare Conference. The all-virtual conference is scheduled for July 13–14, 2021. Tryp chair and CEO Greg McKee, president and chief science officer […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Targets Academic Collaborations to Advance Research on Largely Ignored Indications for Psilocybin
June 3, 2021
Psychedelics have been on the receiving end of groundbreaking research, which have greatly influenced the medical acceptance of the compounds Pharmaceutical developer Tryp Therapeutics is looking to use existing preclinical and clinical data to proceed directly to Phase 2a clinical trials The company intends to contribute to the growing body of research through academic collaborations […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) to Present at Upcoming H.C. Wainwright Psychedelics Conference
June 2, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW), a pharmaceutical company focused on developing compounds for diseases with unmet medical needs through accelerated regulatory pathways, has announced that it will be presenting at H.C. Wainwright & Co.’s Psychedelics in Psychiatry and Beyond conference. The virtual event will be held on June 17, 2021. At the […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Building Psychedelic Medicine Program on Foundation of Strong Leadership, Pharmaceutical Alliances
May 28, 2021
Pharmaceutical developer Tryp Therapeutics is focused on producing novel bioscience solutions for conditions with unmet needs Tryp’s current flagship program involves development of a synthetic psychedelic drug candidate for treating specific pain and eating disorder indications The company expects to begin manufacturing its initial oral psilocybin formulation in September 2021 Tryp’s scientific and executive team […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Partnership with CDMO Alcami for Exclusive Product Formulation
May 25, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing clinical-stage compounds for the treatment diseases with unmet medical needs through accelerated regulatory pathways, has entered into an agreement with Alcami Corporation, a global pharmaceutical contract development and manufacturing organization (“CDMO”). The agreement marks Tryp’s next step in the proprietary manufacturing, formulation and […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Upcoming Drug Candidate Trial Rides Swell of Groundbreaking Psychedelic Medicine Efforts
May 24, 2021
Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Brings Best-in-Class Team to Psychedelics Development
May 21, 2021
NEW YORK, May 21, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announces the availability of a broadcast titled, “Wall Street Unicorns in Process of Changing the Healthcare Landscape.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/QOAcO Most people may not recognize some of the […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Leverages Key Initiatives to Advance Drug Candidates
May 20, 2021
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs. “Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (‘PFN’(TM)) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas,” reads a recent […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Bringing Diversified Pipeline to Psychedelic Revival
May 19, 2021
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Wall Street Unicorns in Process of Changing the […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Shares Six Keys to Leadership Growth in “Forbes” Article
May 14, 2021
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) CEO Greg McKee was featured in a recent “Forbes” article touting six keys to leadership growth. In the article, McKee shared valuable insight into the most effective ways that leaders can grow and develop. The behaviors McKee encouraged include staying curious and stepping outside of your comfort zone […]
Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Builds Alliances Ahead of Psychedelic Drug Trial for Eating Disorders
May 13, 2021
Orphan-stage pharmaceutical innovator Tryp Therapeutics is dedicated to developing novel therapies for medical conditions with unmet needs Tryp’s embrace of psychedelic drug potential is demonstrated in its advancing clinical trials seeking an answer to eating disorders such as binge eating and hyperphagia The company is also developing a clinical trial to address the needs of […]